About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the ...

Merck , known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held clinical-stage biotechnology company, today announced that Merck has entered into an ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

Merck & Co Inc. (MRK) and LaNova Medicines Ltd., a privately held clinical-stage biotechnology company Thursday said Merck has ...

The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...

Merck (MRK) and LaNova Medicines, a privately held clinical-stage biotechnology company, announced that Merck has entered into an exclusive ...

Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.

Merck (NYSE:MRK) and LaNova Medicines announced Thursday an agreement under which the U.S. pharmaceutical giant is expected ...

BMO analyst Evan Seigerman said the LaNova deal offers a hedge to Merck after the data shown by Summit and others. "The ...

The global major depressive disorder (MDD) treatment market is expected to experience steady growth, projected to develop at ...

The global fatty liver treatment market, valued at approximately USD 20 Billion in 2022, is anticipated to witness ...